Heart Drug's Real-World performance under the microscope
NCT ID NCT07168655
First seen Nov 01, 2025 · Last updated Apr 20, 2026 · Updated 22 times
Summary
This study looked at how a drug called mavacamten works for people with obstructive hypertrophic cardiomyopathy (oHCM) in real-world medical practice, not just in a controlled trial. Researchers followed 163 adult patients at a single hospital in the US who were prescribed the drug. They collected information on patients' symptoms, heart function, and overall health to understand the drug's effects in everyday use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.